PMSI supports NorthEdge’s investment into Antibody Analytics

NorthEdge have completed a multi-million-pound investment into Antibody Analytics (AA), a contract research organisation (CRO) and trusted provider of immunology research services to an international client base, to support their continued growth.

Headquartered in Scotland, AA stands at the intersection of cutting-edge research and customer-centric services in the field of pre-clinical drug discovery. The business supports biopharmaceutical companies globally to overcome substantial scientific challenges by providing data of outstanding quality to expedite new healthcare solutions and improve global health outcomes. Antibody Analytics is focused on supporting the developers of antibody-targeted therapeutics, complex biologics and immunotherapies, to help their clients get the best drug candidates into the clinic.

The strategic investment represents an exciting new chapter for the organisation, which will include significant job creation and expansion of its site – resulting in a world-class facility that will provide additional capacity and enable increased research capabilities, allowing the business to continue to develop pioneering solutions. The extended and upgraded facilities will house the latest high-tech equipment, ensuring that the company remains at the forefront of innovative research.

In line with Scotland’s ambitious Life Sciences strategy, this significant investment will also enable a multitude of job opportunities, not just within AA, but also in the broader Scottish Life Sciences sector, promising stability and growth for the region. Whilst AA will continue to be recognised as a regional powerhouse, the investment will reinforce its position as a recognised global leader in pre-clinical immunology research services.

PMSI provided CDD to support the transaction, and addressed key investment themes including customer purchasing dynamics, AA’s competitive positioning, and a scientific assessment of both the global pipeline of novel immunology-based therapeutics and relevant immunology-based assays to demonstrate AA’s current capabilities and highlight relevant growth opportunities.

NorthEdge completes multi-million-pound investment into Antibody Analytics